2.4.1.9 Html 321 539 1 false 98 0 false 5 false false R1.htm 00090 - Document - Document and Entity Information Sheet http://www.amagpharma.com/role/DocumentDocumentAndEntityInformation Document and Entity Information true false R2.htm 00100 - Statement - Consolidated Balance Sheets Sheet http://www.amagpharma.com/role/StatementConsolidatedBalanceSheets Consolidated Balance Sheets false false R3.htm 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Sheet http://www.amagpharma.com/role/StatementConsolidatedBalanceSheetsParenthetical Consolidated Balance Sheets (Parenthetical) false false R4.htm 00200 - Statement - Consolidated Statements of Operations Sheet http://www.amagpharma.com/role/StatementConsolidatedStatementsOfOperations Consolidated Statements of Operations false false R5.htm 00300 - Statement - Consolidated Statements of Comprehensive Income (Loss) Sheet http://www.amagpharma.com/role/StatementConsolidatedStatementsOfComprehensiveIncomeLoss Consolidated Statements of Comprehensive Income (Loss) false false R6.htm 00400 - Statement - Consolidated Statements of Stockholders' Equity Sheet http://www.amagpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquity Consolidated Statements of Stockholders' Equity false false R7.htm 00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Sheet http://www.amagpharma.com/role/StatementConsolidatedStatementsOfStockholdersEquityParenthetical Consolidated Statements of Stockholders' Equity (Parenthetical) false false R8.htm 00500 - Statement - Consolidated Statements of Cash Flows Sheet http://www.amagpharma.com/role/StatementConsolidatedStatementsOfCashFlows Consolidated Statements of Cash Flows false false R9.htm 10101 - Disclosure - Description of Business Sheet http://www.amagpharma.com/role/DisclosureDescriptionOfBusiness Description of Business false false R10.htm 10201 - Disclosure - Summary of Significant Accounting Policies Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies false false R11.htm 10301 - Disclosure - Business Combinations Sheet http://www.amagpharma.com/role/DisclosureBusinessCombinations Business Combinations false false R12.htm 10401 - Disclosure - Investments Sheet http://www.amagpharma.com/role/DisclosureInvestments Investments false false R13.htm 10501 - Disclosure - Fair Value Measurements Sheet http://www.amagpharma.com/role/DisclosureFairValueMeasurements Fair Value Measurements false false R14.htm 10601 - Disclosure - Accounts Receivable, Net Sheet http://www.amagpharma.com/role/DisclosureAccountsReceivableNet Accounts Receivable, Net false false R15.htm 10701 - Disclosure - Inventories Sheet http://www.amagpharma.com/role/DisclosureInventories Inventories false false R16.htm 10801 - Disclosure - Property and Equipment, Net Sheet http://www.amagpharma.com/role/DisclosurePropertyAndEquipmentNet Property and Equipment, Net false false R17.htm 10901 - Disclosure - Goodwill and Intangible Assets, Net Sheet http://www.amagpharma.com/role/DisclosureGoodwillAndIntangibleAssetsNet Goodwill and Intangible Assets, Net false false R18.htm 11001 - Disclosure - Current and Long- Term Liabilities Sheet http://www.amagpharma.com/role/DisclosureCurrentAndLongTermLiabilities Current and Long- Term Liabilities false false R19.htm 11101 - Disclosure - Income Taxes Sheet http://www.amagpharma.com/role/DisclosureIncomeTaxes Income Taxes false false R20.htm 11201 - Disclosure - Accumulated Other Comprehensive Income (Loss) Sheet http://www.amagpharma.com/role/DisclosureAccumulatedOtherComprehensiveIncomeLoss Accumulated Other Comprehensive Income (Loss) false false R21.htm 11301 - Disclosure - Equity-Based Compensation Sheet http://www.amagpharma.com/role/DisclosureEquityBasedCompensation Equity-Based Compensation false false R22.htm 11401 - Disclosure - Employee Savings Plan Sheet http://www.amagpharma.com/role/DisclosureEmployeeSavingsPlan Employee Savings Plan false false R23.htm 11501 - Disclosure - Stockholders' Equity Sheet http://www.amagpharma.com/role/DisclosureStockholdersEquity Stockholders' Equity false false R24.htm 11601 - Disclosure - Business Segments Sheet http://www.amagpharma.com/role/DisclosureBusinessSegments Business Segments false false R25.htm 11701 - Disclosure - Commitments and Contingencies Sheet http://www.amagpharma.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies false false R26.htm 11801 - Disclosure - Collaborative Agreements Sheet http://www.amagpharma.com/role/DisclosureCollaborativeAgreements Collaborative Agreements false false R27.htm 11901 - Disclosure - Debt Sheet http://www.amagpharma.com/role/DisclosureDebt Debt false false R28.htm 12001 - Disclosure - Restructuring Sheet http://www.amagpharma.com/role/DisclosureRestructuring Restructuring false false R29.htm 12101 - Disclosure - Consolidated Quarterly Financial Data-Unaudited Sheet http://www.amagpharma.com/role/DisclosureConsolidatedQuarterlyFinancialDataUnaudited Consolidated Quarterly Financial Data-Unaudited false false R30.htm 12201 - Disclosure - Valuation and Qualifying Accounts Sheet http://www.amagpharma.com/role/DisclosureValuationAndQualifyingAccounts Valuation and Qualifying Accounts false false R31.htm 12301 - Disclosure - Recently Issued and Proposed Accounting Pronouncements Sheet http://www.amagpharma.com/role/DisclosureRecentlyIssuedAndProposedAccountingPronouncements Recently Issued and Proposed Accounting Pronouncements false false R32.htm 20202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) false false R33.htm 30203 - Disclosure - Summary of Significant Accounting Policies (Tables) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables Summary of Significant Accounting Policies (Tables) false false R34.htm 30303 - Disclosure - Business Combination (Tables) Sheet http://www.amagpharma.com/role/DisclosureBusinessCombinationTables Business Combination (Tables) false false R35.htm 30403 - Disclosure - Investments (Tables) Sheet http://www.amagpharma.com/role/DisclosureInvestmentsTables Investments (Tables) false false R36.htm 30503 - Disclosure - Fair Value Measurements (Tables) Sheet http://www.amagpharma.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) false false R37.htm 30603 - Disclosure - Accounts Receivable, Net (Tables) Sheet http://www.amagpharma.com/role/DisclosureAccountsReceivableNetTables Accounts Receivable, Net (Tables) false false R38.htm 30703 - Disclosure - Inventories (Tables) Sheet http://www.amagpharma.com/role/DisclosureInventoriesTables Inventories (Tables) false false R39.htm 30803 - Disclosure - Property and Equipment, Net (Tables) Sheet http://www.amagpharma.com/role/DisclosurePropertyAndEquipmentNetTables Property and Equipment, Net (Tables) false false R40.htm 30903 - Disclosure - Goodwill and Intangible Assets, Net (Tables) Sheet http://www.amagpharma.com/role/DisclosureGoodwillAndIntangibleAssetsNetTables Goodwill and Intangible Assets, Net (Tables) false false R41.htm 31003 - Disclosure - Current and Long-Term Liabilities (Tables) Sheet http://www.amagpharma.com/role/DisclosureCurrentAndLongTermLiabilitiesTables Current and Long-Term Liabilities (Tables) false false R42.htm 31103 - Disclosure - Income Taxes (Tables) Sheet http://www.amagpharma.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) false false R43.htm 31203 - Disclosure - Accumulated Other Comprehensive (Loss) (Tables) Sheet http://www.amagpharma.com/role/DisclosureAccumulatedOtherComprehensiveLossTables Accumulated Other Comprehensive (Loss) (Tables) false false R44.htm 31303 - Disclosure - Equity-Based Compensation (Tables) Sheet http://www.amagpharma.com/role/DisclosureEquityBasedCompensationTables Equity-Based Compensation (Tables) false false R45.htm 31703 - Disclosure - Commitments and Contingencies (Tables) Sheet http://www.amagpharma.com/role/DisclosureCommitmentsAndContingenciesTables Commitments and Contingencies (Tables) false false R46.htm 31903 - Disclosure - Debt (Tables) Sheet http://www.amagpharma.com/role/DisclosureDebtTables Debt (Tables) false false R47.htm 32003 - Disclosure - Restructuring (Tables) Sheet http://www.amagpharma.com/role/DisclosureRestructuringTables Restructuring (Tables) false false R48.htm 32103 - Disclosure - Consolidated Quarterly Financial Data-Unaudited (Tables) Sheet http://www.amagpharma.com/role/DisclosureConsolidatedQuarterlyFinancialDataUnauditedTables Consolidated Quarterly Financial Data-Unaudited (Tables) false false R49.htm 32203 - Disclosure - Valuation and Qualifying Accounts (Tables) Sheet http://www.amagpharma.com/role/DisclosureValuationAndQualifyingAccountsTables Valuation and Qualifying Accounts (Tables) false false R50.htm 40101 - Disclosure - Description of Business (Details) Sheet http://www.amagpharma.com/role/DisclosureDescriptionOfBusinessDetails Description of Business (Details) false false R51.htm 40201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) false false R52.htm 40202 - Disclosure - Summary of Significant Accounting Policies (Details 2) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails2 Summary of Significant Accounting Policies (Details 2) false false R53.htm 40203 - Disclosure - Summary of Significant Accounting Policies (Details 3) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails3 Summary of Significant Accounting Policies (Details 3) false false R54.htm 40204 - Disclosure - Summary of Significant Accounting Policies (Details 4) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails4 Summary of Significant Accounting Policies (Details 4) false false R55.htm 40205 - Disclosure - Summary of Significant Accounting Policies (Details 5) Sheet http://www.amagpharma.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails5 Summary of Significant Accounting Policies (Details 5) false false R56.htm 40301 - Disclosure - Business Combination (Details) Sheet http://www.amagpharma.com/role/DisclosureBusinessCombinationDetails Business Combination (Details) false false R57.htm 40302 - Disclosure - Business Combination (Details 2) Sheet http://www.amagpharma.com/role/DisclosureBusinessCombinationDetails2 Business Combination (Details 2) false false R58.htm 40303 - Disclosure - Business Combination (Details 3) Sheet http://www.amagpharma.com/role/DisclosureBusinessCombinationDetails3 Business Combination (Details 3) false false R59.htm 40401 - Disclosure - Investments (Details) Sheet http://www.amagpharma.com/role/DisclosureInvestmentsDetails Investments (Details) false false R60.htm 40402 - Disclosure - Investments (Details 2) Sheet http://www.amagpharma.com/role/DisclosureInvestmentsDetails2 Investments (Details 2) false false R61.htm 40501 - Disclosure - Fair Value Measurements (Details) Sheet http://www.amagpharma.com/role/DisclosureFairValueMeasurementsDetails Fair Value Measurements (Details) false false R62.htm 40502 - Disclosure - Fair Value Measurements (Details 2) Sheet http://www.amagpharma.com/role/DisclosureFairValueMeasurementsDetails2 Fair Value Measurements (Details 2) false false R63.htm 40601 - Disclosure - Accounts Receivable, Net (Details) Sheet http://www.amagpharma.com/role/DisclosureAccountsReceivableNetDetails Accounts Receivable, Net (Details) false false R64.htm 40701 - Disclosure - Inventories (Details) Sheet http://www.amagpharma.com/role/DisclosureInventoriesDetails Inventories (Details) false false R65.htm 40801 - Disclosure - Property and Equipment, Net (Details) Sheet http://www.amagpharma.com/role/DisclosurePropertyAndEquipmentNetDetails Property and Equipment, Net (Details) false false R66.htm 40901 - Disclosure - Goodwill and Intangible Assets, Net (Details) Sheet http://www.amagpharma.com/role/DisclosureGoodwillAndIntangibleAssetsNetDetails Goodwill and Intangible Assets, Net (Details) false false R67.htm 41001 - Disclosure - Current and Long- Term Liabilities (Details) Sheet http://www.amagpharma.com/role/DisclosureCurrentAndLongTermLiabilitiesDetails Current and Long- Term Liabilities (Details) false false R68.htm 41101 - Disclosure - Income Taxes (Details) Sheet http://www.amagpharma.com/role/DisclosureIncomeTaxesDetails Income Taxes (Details) false false R69.htm 41102 - Disclosure - Income Taxes (Details 2) Sheet http://www.amagpharma.com/role/DisclosureIncomeTaxesDetails2 Income Taxes (Details 2) false false R70.htm 41201 - Disclosure - Accumulated Other Comprehensive Loss (Details) Sheet http://www.amagpharma.com/role/DisclosureAccumulatedOtherComprehensiveLossDetails Accumulated Other Comprehensive Loss (Details) false false R71.htm 41301 - Disclosure - Equity-Based Compensation (Details) Sheet http://www.amagpharma.com/role/DisclosureEquityBasedCompensationDetails Equity-Based Compensation (Details) false false R72.htm 41302 - Disclosure - Equity-Based Compensation (Details 2) Sheet http://www.amagpharma.com/role/DisclosureEquityBasedCompensationDetails2 Equity-Based Compensation (Details 2) false false R73.htm 41303 - Disclosure - Equity-Based Compensation (Details 3) Sheet http://www.amagpharma.com/role/DisclosureEquityBasedCompensationDetails3 Equity-Based Compensation (Details 3) false false R74.htm 41304 - Disclosure - Equity-Based Compensation (Details 4) Sheet http://www.amagpharma.com/role/DisclosureEquityBasedCompensationDetails4 Equity-Based Compensation (Details 4) false false R75.htm 41401 - Disclosure - Employee Savings Plan (Details) Sheet http://www.amagpharma.com/role/DisclosureEmployeeSavingsPlanDetails Employee Savings Plan (Details) false false R76.htm 41501 - Disclosure - Stockholders' Equity (Details) Sheet http://www.amagpharma.com/role/DisclosureStockholdersEquityDetails Stockholders' Equity (Details) false false R77.htm 41601 - Disclosure - Business Segments (Details) Sheet http://www.amagpharma.com/role/DisclosureBusinessSegmentsDetails Business Segments (Details) false false R78.htm 41701 - Disclosure - Commitments and Contingencies (Details) Sheet http://www.amagpharma.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) false false R79.htm 41801 - Disclosure - Collaborative Agreements (Details) Sheet http://www.amagpharma.com/role/DisclosureCollaborativeAgreementsDetails Collaborative Agreements (Details) false false R80.htm 41901 - Disclosure - Debt (Details) Sheet http://www.amagpharma.com/role/DisclosureDebtDetails Debt (Details) false false R81.htm 41902 - Disclosure - Debt (Details 2) Sheet http://www.amagpharma.com/role/DisclosureDebtDetails2 Debt (Details 2) false false R82.htm 42001 - Disclosure - Restructuring (Details) Sheet http://www.amagpharma.com/role/DisclosureRestructuringDetails Restructuring (Details) false false R83.htm 42101 - Disclosure - Consolidated Quarterly Financial Data-Unaudited (Details) Sheet http://www.amagpharma.com/role/DisclosureConsolidatedQuarterlyFinancialDataUnauditedDetails Consolidated Quarterly Financial Data-Unaudited (Details) false false R84.htm 42201 - Disclosure - Valuation and Qualifying Accounts (Details) Sheet http://www.amagpharma.com/role/DisclosureValuationAndQualifyingAccountsDetails Valuation and Qualifying Accounts (Details) false false All Reports Book All Reports Element amag_PaymentsForPurchaseOfConvertibleBondHedge had a mix of decimals attribute values: -5 -3. Element us-gaap_BusinessCombinationAcquisitionRelatedCosts had a mix of decimals attribute values: -5 -3. Element us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInventory had a mix of decimals attribute values: -5 -3. Element us-gaap_CashAndCashEquivalentsAtCarryingValue had a mix of decimals attribute values: -5 -3. Element us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 had a mix of decimals attribute values: -1 0. Element us-gaap_ConvertibleDebtNoncurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_CostOfGoodsSold had a mix of decimals attribute values: -5 -3. Element us-gaap_DebtInstrumentInterestRateStatedPercentage had a mix of decimals attribute values: 3 4. Element us-gaap_InventoryWriteDown had a mix of decimals attribute values: -5 -3. Element us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromIssuanceOfLongTermDebt had a mix of decimals attribute values: -5 -3. Element us-gaap_ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities had a mix of decimals attribute values: -5 -3. Element us-gaap_RatioOfIndebtednessToNetCapital1 had a mix of decimals attribute values: 0 2. Element us-gaap_RestructuringCharges had a mix of decimals attribute values: -5 -3. Element us-gaap_SalesRevenueGoodsNet had a mix of decimals attribute values: -5 -3. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '1/1/2013 - 3/31/2013' is shorter (89 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '4/1/2013 - 6/30/2013' is shorter (90 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '7/1/2013 - 9/30/2013' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '10/1/2013 - 12/31/2013' is shorter (91 days) and has only 3 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '1/1/2014 - 3/31/2014' is shorter (89 days) and has only 2 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '4/1/2014 - 6/30/2014' is shorter (90 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '7/1/2014 - 9/30/2014' is shorter (91 days) and has only 1 values, so it is being removed. Columns in Cash Flows statement 'Consolidated Statements of Cash Flows (USD $)' have maximum duration 365 days and at least 46 values. Shorter duration columns must have at least one fourth (11) as many values. Column '10/1/2014 - 12/31/2014' is shorter (91 days) and has only 3 values, so it is being removed. 'Monetary' elements on report '40101 - Disclosure - Description of Business (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40201 - Disclosure - Summary of Significant Accounting Policies (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40204 - Disclosure - Summary of Significant Accounting Policies (Details 4)' had a mix of different decimal attribute values. 'Monetary' elements on report '40301 - Disclosure - Business Combination (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40302 - Disclosure - Business Combination (Details 2)' had a mix of different decimal attribute values. 'Monetary' elements on report '40303 - Disclosure - Business Combination (Details 3)' had a mix of different decimal attribute values. 'Monetary' elements on report '40502 - Disclosure - Fair Value Measurements (Details 2)' had a mix of different decimal attribute values. 'Monetary' elements on report '40701 - Disclosure - Inventories (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40801 - Disclosure - Property and Equipment, Net (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '40901 - Disclosure - Goodwill and Intangible Assets, Net (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41001 - Disclosure - Current and Long- Term Liabilities (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41101 - Disclosure - Income Taxes (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41102 - Disclosure - Income Taxes (Details 2)' had a mix of different decimal attribute values. 'Monetary' elements on report '41301 - Disclosure - Equity-Based Compensation (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41701 - Disclosure - Commitments and Contingencies (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41801 - Disclosure - Collaborative Agreements (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41901 - Disclosure - Debt (Details)' had a mix of different decimal attribute values. 'Monetary' elements on report '41902 - Disclosure - Debt (Details 2)' had a mix of different decimal attribute values. Process Flow-Through: 00100 - Statement - Consolidated Balance Sheets Process Flow-Through: Removing column 'Dec. 31, 2012' Process Flow-Through: Removing column 'Dec. 31, 2011' Process Flow-Through: 00105 - Statement - Consolidated Balance Sheets (Parenthetical) Process Flow-Through: 00200 - Statement - Consolidated Statements of Operations Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: 00300 - Statement - Consolidated Statements of Comprehensive Income (Loss) Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2014' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2014' Process Flow-Through: Removing column '3 Months Ended Dec. 31, 2013' Process Flow-Through: Removing column '3 Months Ended Sep. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Jun. 30, 2013' Process Flow-Through: Removing column '3 Months Ended Mar. 31, 2013' Process Flow-Through: 00405 - Statement - Consolidated Statements of Stockholders' Equity (Parenthetical) Process Flow-Through: 00500 - Statement - Consolidated Statements of Cash Flows amag-20141231.xml amag-20141231.xsd amag-20141231_cal.xml amag-20141231_def.xml amag-20141231_lab.xml amag-20141231_pre.xml true true